Bipolar and Related Disorders Induced by Sodium 4-Phenylbutyrate in a Male Adolescent with Bile Salt Export Pump Deficiency Disease
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Bile Salt Export Pump (BSEP) Deficiency disease, including Progressive Familial Intrahepatic Cholestasis type 2 (PFIC2), is a rare disease, usually leading within the first ten years to portal hypertension, liver failure, hepatocellular carcinoma. Often liver transplantation is needed. Sodium 4-phenylbutyrate (4-PB) seems to be a potential therapeutic compound for PFIC2. Psychiatric side effects in the adolescent population are little known and little studied since the drug used to treat children and infants. So we described a case of Caucasian boy, suffering from a late onset PFIC2, listed for a liver transplant when he was sixteen and treated with 4-FB (200 mg per kilogram of body weight per day). The drug was discontinued for the onset of bipolar and related disorders. This case illustrates possible psychiatric side effects of the drug.
Abstract
Bile Salt Export Pump (BSEP) Deficiency disease, including Progressive Familial Intrahepatic Cholestasis type 2 (PFIC2), is a rare disease, usually leading within the first ten years to portal hypertension, liver failure, hepatocellular carcinoma. Often liver transplantation is needed. Sodium 4-phenylbutyrate (4-PB) seems to be a potential therapeutic compound for PFIC2. Psychiatric side effects in the adolescent population are little known and little studied since the drug used to treat children and infants. So we described a case of Caucasian boy, suffering from a late onset PFIC2, listed for a liver transplant when he was sixteen and treated with 4-FB (200 mg per kilogram of body weight per day). The drug was discontinued for the onset of bipolar and related disorders. This case illustrates possible psychiatric side effects of the drug.
참고문헌 (24)
- Morotti RA, "Progressive familial intrahepatic cholestasis (PFIC) type 1, 2, and 3: a review of the liver pathology findings", Semin Liver Dis, 31, pp.3~10 (2011)
- Hori T, "Progressive familial intrahepatic cholestasis", Hepatobiliary Pancreat Dis Int, 6, pp.570~578 (2010)
- Soubrane O, "Orthotopic liver transplantation for Byler disease", Transplantation, 50, pp.804~806 (1990)
- Hayashi H, "4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps", Hepatology, 45, pp.1506~1516 (2007)
- Hasegawa Y, "Intractable itch relieved by 4-phenylbutyrate therapy in patients with progressive familial intrahepatic cholestasis type 1", Orphanet J Rare Dis, 9, pp.89~ (2014)
- Naoi S, "Improved liver function and relieved pruritus after 4-phenylbutyrate therapy in a patient with progressive familial intrahepatic cholestasis type 2", J Pediatr, 5, pp.1219~1227 (2014)
- Gonzales E, "Successful mutation specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2", J Hepatol, 57, pp.695~698 (2012)
- Carducci MA, "A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule", Clin Cancer Res, 7, pp.3047~3055 (2001)
- Rubenstein RC, "A pilot clinical trial of oral sodium 4-phenylbutyrate(Buphenyl)in Delta F508-homozygous cystic fibrosis patients : partial restoration of nasal epithelial CFTR function", Am J Respir Crit Care Med, 157, pp.484~490 (1998)
- Olivieri NF, "Treatment of thalassemia major with phenylbutyrate and hydroxyurea", Lancet, 350, pp.491~492 (1997)
- Burlina AB, "Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients", Mol Genet Metab, 72, pp.351~355 (2001)
- Gonzales E, "Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2 : Evidence for improvement of cholestasis with 4-phenylbutyrate", Hepatology, 62, pp.558~566 (2015)
- "European Public Assessment Report of Ammonaps, European Medicine Agency"[URL]
- Bressi C, "Cross validation of the-159-factor structure of the 20-item Toronto Alexithymia Scale : an Italian multicenter study", J Psychosom Res, 41, pp.551~559 (1996)
- Spielberger CD, "STAXI-2: State-Trait Anger Expression Inventory-2: Manual", Adaptation Italian, at Anna Laura Comunian Care, 2004
- Mazzi F, "SCID-II. O.S. The Italian Version" (2003), Special Organizations
- American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders" (2013), American Psychiatric Publishing
- Berg S, "Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate", Cancer Chemother Pharmacol, 47, pp.385~390 (2001)
- Qi X, "Sodium 4-Phenylbutyrate protects against cerebral ischemic injury", Mol Pharmacol, 66, pp.899~908 (2004)
- Anderson G, "Bipolar disorder: role of immune-inflammatory cytokines, oxidative and nitrosative stress and tryptophan catabolites", Curr Psychiatry Rep, 17, pp.8~ (2015)
- Liu M, "Activity of the yeast Tat2p tryptophan permease is sensitive to the anti-tumor agent 4-phenylbutyrate", Curr Genet, 46, pp.256~268 (2004)
- Grzanowski A, "Immunosuppressant-like effects of phenylbutyrate on growth inhibition of Saccharomyces cerevisiae", Curr Genet, 41, pp.142~149 (2002)
- Cho JW, "Pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder using sodium phenylbutyrate", U.S. Patent No 7,968,604, ~ (2011)
- Kulkarnia NN, "Phenylbutyrate induces cathelicidin expression via the vitamin D receptor : Linkage to inflammatory and growth factor cytokines pathways", Mol Immunol, 63, pp.530~539 (2015)